NICE guidance – Discover Pharma

Welcome to Discover Pharma! Today is : October 15, 2026

NICE guidance

Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas
NICE recommends maralixibat for Alagille syndrome itching
NICE has recommended maralixibat for cholestatic pruritus caused by Alagille [...]

October 15, 2026
Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas
NICE recommends NHS access to teplizumab for early type 1 diabetes
The UK health watchdog NICE has recommended NHS reimbursement of [...]

June 22, 2026
Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas
SMC accepts guselkumab for Crohn’s disease and ulcerative colitis in NHS Scotland
The Scottish Medicines Consortium (SMC) has accepted guselkumab for the [...]

May 5, 2026
Advanced Therapies,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas
NICE recommends Johnson & Johnson’s TREMFYA for Crohn’s disease and ulcerative colitis in the UK
The National Institute for Health and Care Excellence (NICE) has [...]

May 5, 2026

main menu

recent posts

get connected

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.

OK